CTOs on the Move

Forest Laboratories

www.frx.com

 
Forest Laboratories is a pharmaceutical company headquartered in New York City, US. The company's research and development spending has grown rapidly in recent years and as of 2007, approached almost a billion US dollars a year, which put it on the list of the top 100 global corporations in R&D spending. Forest Laboratories is also known for licensing European pharmaceuticals for sale in the United States.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.frx.com
  • 909 3rd Ave
    New York, NY USA 10022
  • Phone: 212.421.7850

Executives

Name Title Contact Details

Similar Companies

Pharm-RX Chemical Corp

Pharm-RX Chemical Corp is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sanofi

Sanofi SA is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the worlds fifth-largest by prescription sales.

ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc is a Baudette, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Montana Health Research Inst

Montana Health Research Inst is a Billings, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zentaris

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.